Company
Shanghai Henlius Biotech
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
2
2 still marketed
Novel approvals
0
Approvals since 2021
3
Originals and new uses
Phase 3 trials
30
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
Drugs in development (16)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- SerplulimabHLX10, HLX43Phase 325 trials
Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage
- HLX07Phase 34 trials
Shanghai Henlius Biotech · Colon Cancer Adenocarcinoma, Squamous NSCLC, Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
- HLX22Phase 34 trials
Shanghai Henlius Biotech · HER2 + Breast Cancer, HER2-low Hormone Receptor Positive Breast Cancer, Gastroesophageal-junction Cancer
- EU-sourced KeytrudaPhase 32 trials
Shanghai Henlius Biotech · Non-Squamous Non-Small Cell Lung Cancer, Non Squamous Non Small Cell Lung Cancer
- HLX87Phase 32 trials
Shanghai Henlius Biotech · HER2 + Breast Cancer
- US-sourced KeytrudaPhase 32 trials
Shanghai Henlius Biotech · Non-Squamous Non-Small Cell Lung Cancer, Non Squamous Non Small Cell Lung Cancer
- HLX04-OPhase 31 trial
Shanghai Henlius Biotech · Age Related Macular Degeneration
- HLX11Phase 31 trial
Shanghai Henlius Biotech · Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer
- HLX13Phase 31 trial
Shanghai Henlius Biotech · Hepatocellular Carcinoma (HCC)
- HLX15Phase 31 trial
Shanghai Henlius Biotech · Newly Diagnosed Multiple Myeloma
- HLX17Phase 31 trial
Shanghai Henlius Biotech · Non-Squamous Non-Small Cell Lung Cancer
- HX22Phase 31 trial
Shanghai Henlius Biotech · HER2 + Breast Cancer
- HLX01Phase 21 trial
Shanghai Henlius Biotech · Membranous Nephropathy, Lupus Nephritis (LN)
- HLX26Phase 21 trial
Shanghai Henlius Biotech · NSCLC Stage IV
- HLX53Phase 21 trial
Shanghai Henlius Biotech · Carcinoma, Hepatocellular
- HLX79Phase 21 trial
Shanghai Henlius Biotech · Membranous Nephropathy, Lupus Nephritis (LN)
Recruiting Phase 3 trials
Largest first.
- A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast CancerPivotal-lookingRecruiting
Shanghai Henlius BiotechIndustry
NCT07294508 · 706 participants (planned) · Start Feb 27, 2026 · Primary completion Jan 15, 2028
Drug: HLX87 + HLX22; HLX87 + Pertuzumab and 2 more · For: HER2 + Breast Cancer
Sites: Beijing, China
- A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung CancerPivotal-lookingRecruiting
Shanghai Henlius BiotechIndustry
NCT07459751 · 706 participants (planned) · Start May 27, 2026 · Primary completion Jan 15, 2030
Drug: HLX43; HLX43+HLX07 and 1 more · For: Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
Sites: Beijing, China
- A Clinical Study to Evaluate Efficacy and Safety of Serplulimab(HLX10) Combined With Bevacizumab(HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)Pivotal-lookingRecruiting
Shanghai Henlius BiotechIndustry
NCT04547166 · 568 participants (planned) · Start Mar 10, 2021 · Primary completion Sep 24, 2025
Drug: HLX10; HLX04、 · For: Metastatic Colorectal Cancer
Sites: Guangzhou, China; Hangzhou, China; Linyi, China · 5 sites in all
- A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerPivotal-lookingRecruiting
Shanghai Henlius BiotechIndustry
NCT06532006 · 550 participants (planned) · Start Nov 22, 2024 · Primary completion Jun 1, 2027
Drug: HLX22; Pembrolizumab and 3 more · For: Gastroesophageal-junction Cancer; Monoclonal Antibody; Gastric Cancer and 1 more
Sites: Anaheim, California; Los Alamitos, California; Greeley, Colorado · 208 sites in all
Marketed drugs (2)
Newest FDA action first.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.